FDA Approves Erlotinib (Tarceva) as First-Line Lung Cancer Therapy for Certain Patients

The FDA approved a label expansion for erlotinib (Tarceva), along with the cobas EGFR mutation diagnostic test, to include patients untreated metastatic NSCLC patients whose tumors have either a deletion in exon 19 or exon 21 (L858R) substitution mutations in the EGFR gene.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news